ARTICLE | Clinical News
Olesoxime: Phase II/III data
March 17, 2014 7:00 AM UTC
Top-line data from a double-blind, European, pivotal Phase II/III trial in 165 patients ages 3-25 with type II or non-ambulatory type III SMA showed that once-daily 10 mg/kg oral olesoxime prevented l...